Lilly Ventures has led an $18.5 million round for Intradigm, a Palo Alto-CA-based developer working on RNAi therapeutics. Roche Venture Fund and MP Healthcare Venture Management signed on as well with existing investors Frazier Healthcare Ventures, Alta Partners, MediBic Alliance Technology Fund, and Novartis Venture Fund participating.
"The funding from our Series B financing will allow us to make critical advancements in the development of our RNAi Nanoplex delivery technology, enabling the creation of a pipeline of RNAi therapeutics based on our proprietary siRNA sequences against many high-value cancer targets," said Mohammad Azab, M.D., president and chief executive officer of Intradigm. "The financial strength and industry experience of our expanded investor base is invaluable to Intradigm as we continue to build a high-value company focused on the development and delivery of RNAi therapeutics in areas of unmet medical need."
- check out Intradigm's release